East Coast Biotech Roundup: Bristol, PTC, Ophthotech, & More – Xconomy

East Coast Biotech Roundup: Bristol, PTC, Ophthotech, & More
Xconomy
Ophthotech is currently running three big Phase 3 studies testing the drug in combination with other wet AMD therapies like Novartis/Genentech’s bevacizumab (Lucentis). Shares of Ophthotech jumped more than 24 percent after news of the deal broke.

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment